TM
The future of diagnostics.
is here.
Overview
Shirley Diagnostics leads a revolution, leveraging advances in AI and analytical chemistry to create platform diagnostics for the rapid detection of sepsis and pneumonias as well as predict biomarkers for diagnostic and therapeutic target development.
We leverage ‘omics, especially the untapped metabolomic arena.
How we started.
In 2023, Shirley Diagnostics became the first brand new company to be seeded by the Gates Foundation ($5 M). The founder and CEO, Dr. Jane Hill, an expert in biomarker discovery and med-tech, built out an expert team of technologists and clinical partners
Creating rapid diagnostics for sepsis and pneumonia.
Biomarker prediction with AI and chemistry.
Technologies.
Screening diagnostics for infection. Molecule prediction for diagnostics and therapeutics.
Pipeline.
Rapid detection platforms. Predictive biomarker tools.
Services.
High-resolution chemical analysis. Untargeted 'omic disease biomarker discovery. Specialized contract research.
Searchable biomarker and odor database for human and animal health (Breath Atlas™).
What we do.
Leadership team
Jane Hill, Ph.D.
CEO/Founder
Mary Moul
Business Operations Manager
Anjong Nkengla
Clinical and Research Program Coordinator
Grant Ochoa, Ph.D.
Director of Analytical and Technical Development
Scientific Advisory Board
Heather Bean, Ph.D.
Associate Professor Arizona State University
Jens Herbig, Ph.D.
CTO
IONICON
Makoto Sawano, MD
Professor
Saitama Medical University
Raed Dweik, MD
Chief, Integrated Hospital Care Institute
Cleaveland Clinic
